Polatti F, Perotti F, Filippa N, Gallina D, Nappi R E
Department of Obstetrics and Gynecology (IRCCS Policlinico S. Matteo), Pavia, Italy.
Contraception. 1995 Apr;51(4):221-4. doi: 10.1016/0010-7824(95)00036-a.
A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 micrograms + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p < 0.01) in the bone mass content at the end of the time of observation (+7.8% after 5 years). No significant changes were found in serum alkaline phosphatase levels and in urinary excretion of OH-proline at the end of the study in comparison with basal levels in both groups. Our data suggested that long-term treatment with an oral monophasic contraceptive formulation (ethinylestradiol 20 micrograms + desogestrel 0.150 mg) did not modify the BMD but prevented the occurrence of the physiologic peak of bone mass in young women.
一项前瞻性研究旨在调查服用单相口服避孕药制剂（炔雌醇20微克+去氧孕烯0.150毫克）达5年的年轻女性的骨代谢情况。19至22岁的健康女性（n = 200）被分为两组。A组接受口服避孕药，B组未接受任何治疗。所有受试者在基线时以及5年期间每12个月接受一次使用双能X线吸收仪（Norland XR - 26）对L2 - L4椎体水平的骨密度（BMD）评估，以及血清碱性磷酸酶水平和尿羟脯氨酸排泄量的测量。我们的结果表明，A组在接受5年口服避孕药治疗后未显示出任何显著的骨密度变化，而B组在观察期结束时骨量含量显著增加（p < 0.01）（5年后增加了+7.8%）。与两组的基础水平相比，研究结束时血清碱性磷酸酶水平和尿羟脯氨酸排泄量均未发现显著变化。我们的数据表明，长期使用单相口服避孕药制剂（炔雌醇20微克+去氧孕烯0.150毫克）不会改变骨密度，但可防止年轻女性出现生理性骨量峰值。
